Recent clinical studies in basal cell carcinoma (BCC), a frequent SHH-driven tumor, showed that SMO genetic alterations include ligand binding pocket (LBP) mutations, which define sites of inhibitor binding, as well as mutations in structural pivot regions conferring constitutive receptor activity and drug resistance. Here, SHH is linked to neoplasm.